Extended-spectrum β-lactamase producing Escherichia coli: Changing epidemiology and clinical impact

Current Opinion in Infectious Diseases

Volumn 23, Issue 4, 2010, Pages 320-326

  Oteo, Jesús ^a   Pérez Vázquez, María ^a   Campos, José ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CSIC   (Spain)

Author keywords

epidemiology; Escherichia coli; extended spectrum lactamase

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; NITROFURANTOIN; TIGECYCLINE; TOBRAMYCIN; BETA LACTAMASE; BETA-LACTAMASE CTX-M-15; ESCHERICHIA COLI PROTEIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIUM ISOLATION; COMMUNITY CARE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; MORTALITY; NONHUMAN; PANDEMIC; REVIEW; RISK FACTOR; URINARY TRACT INFECTION; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; HETEROZYGOTE; METABOLISM; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; PATHOGENICITY;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARRIER STATE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; MOLECULAR EPIDEMIOLOGY; RISK FACTORS;

EID: 77954879314     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283398dc1     Document Type: Review

References (67)

1. Livermore DM. Defining an extended-spectrum p-lactamase. Clin Microbiol Infect 2008; 14 (Suppl. 1):3-10.
2. Talbot GH, Bradley J, Edwards JE, etal. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Available Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-668. (Pubitemid 43271379)
3. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35:316-321.
4. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13(47): 19044.
5. Forssten SD, Kolho E, Lauhio A, etal. Emergence of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates during the years 2000 and 2004 in Helsinki, Finland. Clin Microbiol Infect 2009 [Epub ahead of print].
6. Pitout JD, Gregson DB, Campbell L, et al. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteraemia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53:2846-2851.
7. Rodríguez-BañoJ, Picon E, Gijon P, etal. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40-48.
8. Rodríguez-Baño J, Alcala J, Cisneros JM, et al. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother 2009; 63:781-784.
9. Peirano G, Richardson D, Nigrin J, et al. High diversity od ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-p-lacta-mase- producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother 2010; 54:1327-1330.
10. Severin JA, Mertaniasih NM, Kuntaman K, et al. Molecular characterization of extended-spectrum beta-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia. J Antimicrob Chemother 2010; 65:465-469.
11. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-p-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008; 52:3244-3252.
12. Lau SH, Kaufmann ME, Livermore DM, et al. UK epidemic Escherichia coli strain A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother 2008; 62:1241-1244.
13. Blanco M, Alonso MP, Nicolas-Chanoine MH, etal. Molecular epidemiology of Escherichia coliproducing extended-spectrum p-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2009; 63:1135-1141.
14. Naseer U, Haldorsen B, Tofteland S, etal. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009; 117:526-536.
15. McGettigan SE, Hu B, Andreacchio K, et al. Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania. J Clin Microbiol 2009; 47:2970-2974.
16. Sidjabat HE, Paterson DL, Adams-Haduch J, etal. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in Western Pennsylvania. Antimicrob Agents Chemother 2009; 53:4733-4739.
17. Hanson ND, Smith Molan E, Hong SG, et al. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 p-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob Agents Chemother 2008; 52:3814-3816.
18. Arpin C, Quentin C, Grobost F, etal. Nationwide survey of extended-spectrum p-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009; 63:1205-1214.
19. Mshana SE, Imirzalioglu C, Hossain H, et al. Conjugative IncFI plasmids carrying CTX-M-15 among Escherichia coli ESBL producing isolates at a University hospital in Germany. BMC Infect Dis 2009; 9:97.
20. Oteo J, Diestra K, Juan C, et al. Extended-spectrum beta-lactamase-produ- cing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10complex/A, ST23complex/Aand ST131/B2. Int J Antimicrob Agents 2009; 34:173-176.
21. Sturm PD, Bochum ET, Van Mook-Vermulst SV, etal. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxyto-ca at the Radboud University Nijmegen Medical Centre in the Netherlands. Microb Drug Resist 2010 [Epub ahead of print].
22. Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009; 53:3280-3284.
23. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In-vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intraabdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009; 34(6):585-588.
24. Tian GB, Wang HN, Zou LK, et al. Detection of CTX-M-15, CTX-M-22, and SHV-2 extended-spectrum beta-lactamases (ESBLs) in Escherichia coli fecal-sample isolates from pig farms in China. Foodborne Pathog Dis 2009; 6:297-304.
25. Yuan L, Liu JH, Hu GH, etal. Molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli isolates from chickens in Henan Province, China. J Med Microbiol 2009; 58:1449-1453.
26. Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54:781-785.
27. Liu W, Chen L, Li H, etal. Novel CTX-M p-lactamase genotype distribution and spread into multiple species of Enterobacteriaceae in Changsha, Southern China. J Antimicrob Chemother 2009; 63:895-900.
28. Suzuki S, Shibata N, Yamane K, etal. Change in the prevalence of extended-spectrum-p-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009; 63:72-79.
29. CTX-M within an Australian extended-spectrum beta-lactamase gene pool. Antimicrob Agents Chemother 2008; 52:4198-4202.
30. Machado E, Coque TM, Canton R, etal. Antibiotic resistance integrons and extended-spectrum p-lactamases among Enterobacteriaceae isolates recovered from chickens and swine in Portugal. J Antimicrob Chemother 2008; 62:296-302.
31. Ben Slama K, Jouini A, Ben Sallem R, et al. Prevalence of broad-spectrum cephalosporin-resistant Escherichia coli isolates in food samples in Tunisia, and characterization of integrons and antimicrobial resistance mechanisms implicated. Int J Food Microbiol 2010; 137:281-286.
32. Vinue L, Saenz Y, Mart́nez S, et al. Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin Microbiol Infect 2009; 15:954-957.
33. Rodríguez-Baño J, Lopez-Cerero L, Navarro MD, et al. Faecal carriage of extended-spectrum p-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62:1142-1149.
34. Guimaraes B, Barreto A, Radhouani H, et al. Genetic detection of extended-spectrum beta-lactamase-containing Escherichia coli isolates and vancomy-cin-resistant enterococci in fecal samples of healthy children. Microb Drug Resist 2009; 15:211-216.
35. Reinthaler FF, Feierl G, Galler H, et al. ESBL-producing E. coli in Austrian sewage sludge. Water Res 2010; 44:1981-1985.
36. Costa D, Vinue L, Poeta P, et al. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolates in faecal samples of broilers. Vet Microbiol 2009; 138:339-344.
37. Yuan L, Liu JH, Hu GZ, etal. Molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli isolates from chickens in Henan Province, China. J Med Microbiol 2009; 58:1449-1453.
38. Sun Y, Zeng Z, Chen S, et al. High prevalence of bla extended-spectrum beta(CTX-M)-lactamase genes in Escherichia coli isolates from pets and emergence of CTX-M-64 in China. Clin Microbiol Infect 2009 [Epub ahead of print].
39. Bonnedahl J, Drobni M, Gauthier-Clerc M, et al. Dissemination of Escherichia coli with CTX-M type ESBL between humans and yellow-legged gulls in the south of France. PLoS One 2009; 4(6):e5958.
40. Poeta P, Radhouani H, Pinto L, et al. Wild boars as reservoirs of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli of different phylogenetic groups. J Basic Microbiol 2009; 49:584-588.
41. Literak I, Dolejska M, Radimersky T, et al. Antimicrobial-resistant faecal Escherichia coli in wild mammals in central Europe: multiresistant Escherichia coli producing extended-spectrum beta-lactamases in wild boars. J Appl Microbiol 2009 [Epub ahead of print].
42. Rooney PJ, O'Leary MC, Loughrey AC, etal. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009; 64:635-641.
43. March A, Aschbacher R, Dhanji H, etal. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect 2009 [Epub ahead of print].
44. Sasaki T, Hirai I, Niki M, et al. High prevalence of CTX-M beta-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. J Antimicrob Chemother 2010; 65:666-668.
45. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65:333-341.
46. Kuster SP, Hasse B, Huebner V, et al. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiel la pneumoniae at a tertiary care university hospital in Switzerland. Infection 2010; 38:33-40.
47. Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enter obacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682-690.
48. Rodríguez-Baño J, AlcalaJC, CisnerosJM, etal. Community infections caused by extended-spectrum p-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168:1897-1902.
49. Azap OK, Arslan H, Serefhanoglu K, etal. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16:147-151.
50. Laupland KB, Church DL, Vidakovich J, et al. Community-onset extended-spectrum p-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008; 57:441-448.
51. Freeman JT, McBridge SJ, Hefferman H, et al. Community-onset genitourinary infection due to CTX-M-15-producing Escherichia coli among travellers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008; 47:689-692.
52. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58:299-307.
53. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63:568-574.
54. Lee CI, Lee NY, Yan JJ, et al. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. J Microbiol Inmunol Infect 2009; 42:303-309.
55. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST1 31-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64:712-717.
56. Rodríguez-Baño J, Navarro MD. Extended-spectrum p-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect 2008; 14 (Suppl. 1): 104-110.
57. Oteo J, Navarro C, Cercenado E, et al. High-level of cefotaxime and ceftazidime resistance in Escherichia coli: spread of clonal and unrelated isolates between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 2006; 44:2359-2366.
58. Horcajada JP, Busto M, Grau S, et al. High prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 2009; 74:1195-1199.
59. Lee CH, Su LH, Lin WC, et al. Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen. Int J Infect Dis 2009 [Epub ahead of print].
60. Song KH, Jeon JH, ParkWB, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009; 9:41.
61. Vigil KJ, Johnson JR, Johnston BD, et al. Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 2010; 50:374-380.
62. Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008; 32:534-537.
63. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008; 62:895-904.
64. Lu CT, Chuang YC, Sun W, et al. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2008; 32 (Suppl 3):S179-S183.
65. Woodford N, Caratolli A, Karisik E, et al. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK51 6, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international clone O25:H4-ST131 clone. Antimicrob Agents Chemother 2009; 53:4472-4482.
66. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200.
67. Falagas ME, Kastoris AC, Kaspakelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum p-lac-tamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50.